Remarkably, CGL1 exhibited a much stronger inhibition effect than AAL and CGL2, with 75 or 60% decreased ratios of tumor weight in two models, indicating that CGL1 has application potential in colorectal cancer treatment. Here, GZMB is linked to colorectal cancer.